


**REMARKS**

The present application is identical to USSN 07/265,829, filed October 31, 1988, which is a priority application for the pending parent application (USSN 08/472,760). The '829 application is incorporated by reference in the first paragraph of the pending parent application. Thus, the effective filing date of the present application is, at the latest, October 31, 1988.

If a telephone conference would expedite prosecution of this application, the Examiner is invited to telephone the undersigned at 415-576-0200.

Respectfully submitted,

  
Kevin L. Bastian  
Reg. No. 34,774

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, California 94111-3834  
Tel: (415) 576-0200  
Fax: (415) 576-0300

SF 1303190 v1

1003323001

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**In the claims:**

--48.(New) A method of suppressing the neoplastic phenotype of a cancer cell, the method comprising contacting the cell with a nucleic acid encoding a full length, wild type retinoblastoma protein. --

10028726-100404